Sally Woodhouse consults on pharmaceutical and healthcare matters involving antitrust, product misrepresentation, intellectual property, False Claims Act, breach of contract, and securities fraud allegations. Dr. Woodhouse is a former cohead of Cornerstone Research’s life sciences practice.
Life sciences
Dr. Woodhouse’s experience in life sciences antitrust matters includes assessing the appropriateness of class certification, analyzing relevant markets and competitive effects, and estimating damages. These cases have involved allegations of delayed or suppressed generic competition related to reverse payment settlements, product hopping, risk evaluation and mitigation strategy (REMS) programs, and noncompete agreements.
Dr. Woodhouse has also analyzed:
- Pharmaceutical pricing practices in the context of average wholesale price (AWP) litigation
- Commercial reasonableness of drug development and commercialization efforts in breach of contract matters
- Damages, commercial success, and irreparable harm in pharmaceutical patent infringement matters
- Damages and class certification issues in pharmaceutical improper marketing matters
- Company clinical trial protocols, analyses of clinical trial data, and other biostatistics issues arising in securities and product misrepresentation matters
- Competitive effects of a merger of biopharmaceutical companies, including the ability and incentives of the combined entity to employ bundled rebates to foreclose competition
Healthcare
Dr. Woodhouse has consulted on healthcare matters involving health insurance companies, physicians groups, hospitals, and pharmacies, including retail, specialty, and long-term care pharmacies. Her work on these matters has included assessing merger effects, monopolization claims, and reimbursement disputes, among other topics.
Other litigation
Dr. Woodhouse has consulted on cases in a number of other industries, including automotive, consumer products, financial institutions, and high tech.
ICC Arbitration Involving Commercially Reasonable Efforts to Develop and Commercialize a Drug
- Value Drug Company v. Takeda Pharmaceuticals U.S.A. Inc. et al.
- In re Novartis and Par Antitrust Litigation
- Amgen Inc.’s Acquisition of Horizon Therapeutics plc
- In re HIV Antitrust Litigation
- Pro Bono: Cornerstone Research Supports Efforts to Protect Voting Rights
- Alleged Failure to Disclose Drug Safety Issues
- ICC Arbitration Involving Commercially Reasonable Efforts to Develop and Commercialize a Drug
- Hsu et al. v. Puma Biotechnology Inc. et al.
- United States of America ex rel. Susan Ruscher et al. v. Omnicare Inc. et al.
- Reverse Payments Settlement Analysis
- Cornerstone Research Staff and Expert Sign Amici Curiae Brief for U.S. First Circuit
- Cornerstone Research Coauthors Antitrust Amicus Curiae Brief for U.S. Third Circuit
- Cornerstone Research Coauthors Antitrust Amicus Brief for Supreme Court
- Off-Label Marketing
- Market Timing
- Average Wholesale Price Litigation
- Commercial Success
- Damages in Life-Cycle Management Case
- Delayed Generic Competition
- Irreparable Harm
- In re Ovcon Antitrust Litigation
- Pharmaceutical Marketing
|
|
|
|
